Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

The agent is composed of 2 active ingredients with synergistic anti-oxidant and anti-inflammatory effects which can reduce brain cell injury or impairment caused by acute ischemic stroke. 

FDA Grants Breakthrough Therapy Designation to Edaravone Dexborneol Combination Therapy for Acute Ischemic Stroke

Videos

In this discussion, the pair of neurologists explore the latest drug development and ongoing clinical trials for MOGAD, a rare neuroimmune disorder. [WATCH TIME: 4 minutes]

Evaluating the Treatment Pipeline for MOGAD

Neal K. Shah, CEO of CareYaya Health Technologies, discussed how Apple's new health features could potentially be a game-changer for neurological health. 

Apple's Latest Health Updates: A Neurological Game-Changer in Disguise

In this segment, Bennett and Greenberg explore the diagnosis, acute treatment, and long-term management of MOGAD, highlighting current therapies and ongoing research. [WATCH TIME: 8 minutes]

Understanding the Treatments and Tools for MOGAD Management

, has been with the team since October 2019. Follow him on Twitter 

In this episode, Greenberg and Bennett provide some perspective on the fluidity of MOGAD diagnosis and how it could potentially change over time as more is understood about neuroimmune disorders. [WATCH TIME: 5 minutes]

Continuing Evolution of MOGAD Diagnosis, Remaining Questions in Antibody Titer Testing

In this segment, the duo of neurologists provided a number of informative considerations treating clinicians should take when diagnosing MOGAD, emphasizing careful testing and interpretation of data in this complex process. [WATCH TIME: 4 minutes]

Navigating MOGAD Diagnosis: Clinical Insights and Key Considerations

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

YouTube

Spotlight

AAIC 2024

FEATURE: Long COVID’s Neurological Toll

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Slideshows

Dr. Loeb summarizes a global and one-of-a-kind approach of biomarker and drug discovery using systems biology of human brain tissues.

Clinical

The Human Epilepsy Project